Evaluation of dosing strategies and trough concentrations of vancomycin in patients undergoing continuous venovenous hemofiltration

被引:8
|
作者
Wahby, Krista A. [1 ]
Cunmuljaj, Lejla [1 ]
Mouabbi, Karim [1 ]
Almadrahi, Zinah [1 ]
Wilpula, Liz [1 ]
机构
[1] Harper Univ Hosp, Detroit, MI USA
来源
PHARMACOTHERAPY | 2021年 / 41卷 / 07期
关键词
CVVH; CRRT; dosing; renal replacement; vancomycin; CRITICALLY-ILL PATIENTS; PROTEIN-BINDING; PHARMACOKINETICS; RECOMMENDATIONS; CLEARANCE;
D O I
10.1002/phar.2535
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study Objective Recommendations regarding vancomycin dosing in critically ill patients on continuous venovenous hemofiltration (CVVH) are limited. The purpose of this study was to evaluate current dosing practices of pharmacists for patients treated with CVVH, develop guidelines for optimal dosing and monitoring of vancomycin to improve target trough attainment, and reduce pharmacist workload. Design A retrospective cohort study. was performed of critically ill adult patients from January 2015 to December 2018. Patients were included if they received vancomycin during CVVH for at least 48 h. Patients with significant residual kidney function, defined as daily urine output >400 ml or significant fluctuations (>= 1000 ml/h in a 24-h period) in their hemofiltration rates, were excluded. Interruptions in CVVH up to 6 h/day were permitted. Dosing strategies with two dosing categories were defined: (1) dosing based on random serum levels (dosing by level, DBL) or (2) scheduled vancomycin dosing (SD). Setting Academic medical center in Detroit, Michigan. Patients Critically ill adult patients. Measurements and Main Results During the study period, 942 patients were evaluated and 200 met inclusion criteria, for a total of 586 serum vancomycin levels. There were 141 patients with 443 random vancomycin serum levels in the DBL group and 59 patients with143 vancomycin trough levels in the SD group. Mean vancomycin trough levels were similar between groups (17.1 +/- 6 vs. 16.5 +/- 4 mcg/ml) for the DBL and SD groups, respectively. For the primary end point of overall target trough achievement of 15-20 mcg/ml, significantly more trough levels in the SD group were in the 15-20 mcg/ml range compared with the DBL group, 50% vs. 38%; p < 0.001, respectively. When target trough range was extended to 10-20 mcg/ml, success rates were similar between groups (74% DBL vs. 82% SD, p = 0.021). The number of interventions required by the pharmacist, including notes per day and orders per day, were reduced by approximately 50% when the SD strategy was utilized. Scheduled vancomycin dosing regimens of 15-22 mg/kg every 12-24 h were required to yield trough levels in the 15-20 mcg/ml range. Conclusions Target vancomycin trough achievement of 15-20 mcg/ml occurred more frequently when vancomycin was scheduled at a dose of 15-22 mg/kg every 12-24 h based on ultrafiltration rate and may alleviate the time and cost associated with frequent vancomycin serum monitoring.
引用
收藏
页码:554 / 561
页数:8
相关论文
共 50 条
  • [41] Predicting mortality in patients on continuous venovenous hemofiltration and hemodiafiltration
    Capella, JM
    Keating, K
    [J]. CRITICAL CARE MEDICINE, 2000, 28 (12) : A117 - A117
  • [42] Plasmapheresis combined with continuous venovenous hemofiltration in patients with sepsis
    Schmidt, J
    Hann, S
    Spelter, H
    Mohr, VD
    Solch, A
    Vogel, P
    Zirngibl, H
    [J]. GASTROENTEROLOGY, 1999, 116 (04) : A1350 - A1350
  • [43] VANCOMYCIN PHARMACOKINETICS IN CRITICALLY ILL PATIENTS DURING ACCELERATED VENOVENOUS HEMOFILTRATION
    Lopez, Natasha
    Sin, Jonathan
    Griggs, Michael
    [J]. CRITICAL CARE MEDICINE, 2022, 50 (01) : 440 - 440
  • [44] SIMULATION OF VANCOMYCIN PEAK AND TROUGH CONCENTRATIONS USING 5 DOSING METHODS IN 37 PATIENTS
    ZOKUFA, HZ
    RODVOLD, KA
    BLUM, RA
    RIFF, LJ
    FISCHER, JH
    CROSSLEY, KB
    ROTSCHAFER, JC
    [J]. PHARMACOTHERAPY, 1989, 9 (01): : 10 - 16
  • [45] Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration
    Tegeder, I
    Neumann, F
    Bremer, F
    Brune, K
    Lötsch, J
    Geisslinger, G
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (01) : 50 - 57
  • [46] Cytokine removal in septic patients with continuous venovenous hemofiltration
    Heering, P
    Grabensee, B
    Brause, M
    [J]. KIDNEY & BLOOD PRESSURE RESEARCH, 2003, 26 (02): : 128 - 134
  • [47] Trace element and vitamin concentrations and losses in critically ill patients treated with continuous venovenous hemofiltration
    Story, DA
    Ronco, C
    Bellomo, R
    [J]. CRITICAL CARE MEDICINE, 1999, 27 (01) : 220 - 223
  • [48] Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients
    Guenter, SG
    Iven, H
    Boos, C
    Bruch, HP
    Muhl, E
    [J]. PHARMACOTHERAPY, 2002, 22 (02): : 175 - 183
  • [49] Evaluation of steady state vancomycin trough concentrations post implementation of various dosing regimens.
    Gibson, Matthew
    Mount, Kari
    Wenzler, Eric
    Lundberg, Jordan
    Bauer, Karri
    [J]. PHARMACOTHERAPY, 2014, 34 (10): : E248 - E248
  • [50] Pharmacokinetics of gentamicin and vancomycin during continuous venovenous hemofiltration in critically ill septic patients with acute kidney injury
    N Petejova
    J Duricova
    A Martinek
    J Zahalkova
    [J]. Critical Care, 17 (Suppl 2):